ID   P_HUMAN                 Reviewed;         838 AA.
AC   Q04671; Q15211; Q15212; Q96EN1; Q9UMI5;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   21-MAR-2006, sequence version 2.
DT   28-JUN-2023, entry version 214.
DE   RecName: Full=P protein;
DE   AltName: Full=Melanocyte-specific transporter protein;
DE   AltName: Full=Pink-eyed dilution protein homolog;
GN   Name=OCA2 {ECO:0000312|HGNC:HGNC:8101}; Synonyms=D15S12, P;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 3), AND VARIANT ASP-257.
RX   PubMed=8421497; DOI=10.1038/361072a0;
RA   Rinchik E.M., Bultman S.J., Horsthemke B., Lee S.-T., Strunk K.M.,
RA   Spritz R.A., Avidano K.A., Jong M.T.C., Nicholls R.D.;
RT   "A gene for the mouse pink-eyed dilution locus and for human type II
RT   oculocutaneous albinism.";
RL   Nature 361:72-76(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 1 AND 3), FUNCTION, SUBCELLULAR
RP   LOCATION, AND VARIANTS TRP-305; GLN-419; PHE-440; ARG-615 AND THR-722.
RX   PubMed=7601462; DOI=10.1016/0888-7543(95)80220-g;
RA   Lee S.-T., Nicholls R.D., Jong M.T.C., Fukai K., Spritz R.A.;
RT   "Organization and sequence of the human P gene and identification of a new
RT   family of transport proteins.";
RL   Genomics 26:354-363(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 288-419, AND DISEASE.
RC   TISSUE=Skin;
RX   PubMed=1509264; DOI=10.1126/science.257.5073.1121;
RA   Gardner J.M., Nakatsu Y., Gondo Y., Lee S., Lyon M.F., King R.A.,
RA   Brilliant M.H.;
RT   "The mouse pink-eyed dilution gene: association with human Prader-Willi and
RT   Angelman syndromes.";
RL   Science 257:1121-1124(1992).
RN   [5]
RP   FUNCTION.
RX   PubMed=11310796; DOI=10.1034/j.1600-0749.2001.140203.x;
RA   Brilliant M.H.;
RT   "The mouse p (pink-eyed dilution) and human P genes, oculocutaneous
RT   albinism type 2 (OCA2), and melanosomal pH.";
RL   Pigment Cell Res. 14:86-93(2001).
RN   [6]
RP   POSSIBLE INVOLVEMENT IN SKIN COLOR VARIATION.
RX   PubMed=11601658; DOI=10.1034/j.1600-0749.2001.140508.x;
RA   Manga P., Orlow S.J.;
RT   "Inverse correlation between pink-eyed dilution protein expression and
RT   induction of melanogenesis by bafilomycin A1.";
RL   Pigment Cell Res. 14:362-367(2001).
RN   [7]
RP   FUNCTION.
RX   PubMed=15262401; DOI=10.1016/j.tig.2004.06.010;
RA   Sturm R.A., Frudakis T.N.;
RT   "Eye colour: portals into pigmentation genes and ancestry.";
RL   Trends Genet. 20:327-332(2004).
RN   [8]
RP   REVIEW ON OCA2 VARIANTS.
RX   PubMed=10094567;
RX   DOI=10.1002/(sici)1098-1004(1999)13:2<99::aid-humu2>3.0.co;2-c;
RA   Oetting W.S., King R.A.;
RT   "Molecular basis of albinism: mutations and polymorphisms of pigmentation
RT   genes associated with albinism.";
RL   Hum. Mutat. 13:99-115(1999).
RN   [9]
RP   FUNCTION, AND INDUCTION.
RX   PubMed=22234890; DOI=10.1101/gr.128652.111;
RA   Visser M., Kayser M., Palstra R.J.;
RT   "HERC2 rs12913832 modulates human pigmentation by attenuating chromatin-
RT   loop formation between a long-range enhancer and the OCA2 promoter.";
RL   Genome Res. 22:446-455(2012).
RN   [10]
RP   FUNCTION, DEVELOPMENTAL STAGE, AND TISSUE SPECIFICITY.
RX   PubMed=32966160; DOI=10.1091/mbc.e20-03-0200;
RA   Le L., Escobar I.E., Ho T., Lefkovith A.J., Latteri E.,
RA   Haltaufderhyde K.D., Dennis M.K., Plowright L., Sviderskaya E.V.,
RA   Bennett D.C., Oancea E., Marks M.S.;
RT   "SLC45A2 protein stability and regulation of melanosome pH determine
RT   melanocyte pigmentation.";
RL   Mol. Biol. Cell 31:2687-2702(2020).
RN   [11]
RP   VARIANTS OCA2.
RX   PubMed=7874125;
RA   Lee S.-T., Nicholls R.D., Schnur R.E., Guida L.C., Lu-Kuo J., Spinner N.B.,
RA   Zackai E.H., Spritz R.A.;
RT   "Diverse mutations of the P gene among African-Americans with type II
RT   (tyrosinase-positive) oculocutaneous albinism (OCA2).";
RL   Hum. Mol. Genet. 3:2047-2051(1994).
RN   [12]
RP   VARIANTS OCA2.
RX   PubMed=7762554;
RA   Spritz R.A., Fukai K., Holmes S.A., Luande J.;
RT   "Frequent intragenic deletion of the P gene in Tanzanian patients with type
RT   II oculocutaneous albinism (OCA2).";
RL   Am. J. Hum. Genet. 56:1320-1323(1995).
RN   [13]
RP   VARIANTS OCA2.
RX   PubMed=9259203;
RX   DOI=10.1002/(sici)1098-1004(1997)10:2<175::aid-humu12>3.0.co;2-x;
RA   Spritz R.A., Lee S.-T., Fukai K., Brondum-Nielsen K., Chitayat D.,
RA   Lipson M.H., Musarella M.A., Rosenmann A., Weleber R.G.;
RT   "Novel mutations of the P gene in type II oculocutaneous albinism (OCA2).";
RL   Hum. Mutat. 10:175-177(1997).
RN   [14]
RP   VARIANTS OCA2 ARG-86; PHE-112; VAL-368; ILE-592; PRO-724 AND VAL-787, AND
RP   VARIANT ASP-257.
RX   PubMed=10671067;
RA   Oetting W.S., Gardner J.M., Fryer J.P., Ching A., Durham-Pierre D.,
RA   King R.A., Brilliant M.H.;
RT   "Mutations of the human P gene associated with type II oculocutaneous
RT   albinism (OCA2).";
RL   Hum. Mutat. 12:434-434(1998).
RN   [15]
RP   VARIANTS OCA2 GLY-290; ILE-443; GLU-614; LEU-617; CYS-679; CYS-720; ARG-795
RP   AND VAL-833 DEL, AND VARIANTS TRP-305 AND GLN-419.
RX   PubMed=10987646; DOI=10.1007/s004390051090;
RA   Passmore L.A., Kaesmann-Kellner B., Weber B.H.F.;
RT   "Novel and recurrent mutations in the tyrosinase gene and the P gene in the
RT   German albino population.";
RL   Hum. Genet. 105:200-210(1999).
RN   [16]
RP   VARIANT OCA2 VAL-334, AND VARIANTS UNCLASSIFIED OCA MET-350; THR-370;
RP   LYS-678; PHE-688 AND LEU-743.
RX   PubMed=10649493;
RX   DOI=10.1002/(sici)1098-1004(200002)15:2<166::aid-humu5>3.0.co;2-z;
RA   Kerr R., Stevens G., Manga P., Salm S., John P., Haw T., Ramsay M.;
RT   "Identification of P gene mutations in individuals with oculocutaneous
RT   albinism in sub-Saharan Africa.";
RL   Hum. Mutat. 15:166-172(2000).
RN   [17]
RP   VARIANTS TRP-305 AND GLN-419, AND INVOLVEMENT IN DETERMINATION OF EYE
RP   COLOR.
RX   PubMed=12163334;
RA   Rebbeck T.R., Kanetsky P.A., Walker A.H., Holmes R., Halpern A.C.,
RA   Schuchter L.M., Elder D.E., Guerry D.;
RT   "P gene as an inherited biomarker of human eye color.";
RL   Cancer Epidemiol. Biomarkers Prev. 11:782-784(2002).
RN   [18]
RP   VARIANTS OCA2 GLY-290; ILE-443; ASP-489; CYS-679 AND LEU-743.
RX   PubMed=12876664; DOI=10.1086/377569;
RA   King R.A., Willaert R.K., Schmidt R.M., Pietsch J., Savage S., Brott M.J.,
RA   Fryer J.P., Summers C.G., Oetting W.S.;
RT   "MC1R mutations modify the classic phenotype of oculocutaneous albinism
RT   type 2 (OCA2).";
RL   Am. J. Hum. Genet. 73:638-645(2003).
RN   [19]
RP   VARIANTS OCA2 THR-481 AND HIS-799.
RX   PubMed=12727022; DOI=10.1016/s0923-1811(03)00005-7;
RA   Kato A., Fukai K., Oiso N., Hosomi N., Saitoh S., Wada T., Shimizu H.,
RA   Ishii M.;
RT   "A novel P gene missense mutation in a Japanese patient with oculocutaneous
RT   albinism type II (OCA2).";
RL   J. Dermatol. Sci. 31:189-192(2003).
RN   [20]
RP   VARIANTS OCA2 TRP-10; LEU-198; LEU-211; ILE-394 AND THR-481, AND VARIANTS
RP   MET-387 AND ARG-615.
RX   PubMed=12713581; DOI=10.1046/j.1523-1747.2003.12127.x;
RA   Suzuki T., Miyamura Y., Matsunaga J., Shimizu H., Kawachi Y., Ohyama N.,
RA   Ishikawa O., Ishikawa T., Terao H., Tomita Y.;
RT   "Six novel P gene mutations and oculocutaneous albinism type 2 frequency in
RT   Japanese albino patients.";
RL   J. Invest. Dermatol. 120:781-783(2003).
RN   [21]
RP   VARIANTS TRP-305 AND GLN-419, AND INVOLVEMENT IN SUSCEPTIBILITY TO
RP   MELANOMA.
RX   PubMed=15889046; DOI=10.1038/sj.ejhg.5201415;
RG   Melan-Cohort;
RA   Jannot A.-S., Meziani R., Bertrand G., Gerard B., Descamps V.,
RA   Archimbaud A., Picard C., Ollivaud L., Basset-Seguin N., Kerob D.,
RA   Lanternier G., Lebbe C., Saiag P., Crickx B., Clerget-Darpoux F.,
RA   Grandchamp B., Soufir N.;
RT   "Allele variations in the OCA2 gene (pink-eyed-dilution locus) are
RT   associated with genetic susceptibility to melanoma.";
RL   Eur. J. Hum. Genet. 13:913-920(2005).
RN   [22]
RP   INVOLVEMENT IN SHEP1, AND POLYMORPHISM.
RX   PubMed=17236130; DOI=10.1086/510885;
RA   Duffy D.L., Montgomery G.W., Chen W., Zhao Z.Z., Le L., James M.R.,
RA   Hayward N.K., Martin N.G., Sturm R.A.;
RT   "A three-single-nucleotide polymorphism haplotype in intron 1 of OCA2
RT   explains most human eye-color variation.";
RL   Am. J. Hum. Genet. 80:241-252(2007).
RN   [23]
RP   VARIANT [LARGE SCALE ANALYSIS] THR-773.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
RN   [24]
RP   INVOLVEMENT IN SHEP1, AND POLYMORPHISM.
RX   PubMed=17952075; DOI=10.1038/ng.2007.13;
RA   Sulem P., Gudbjartsson D.F., Stacey S.N., Helgason A., Rafnar T.,
RA   Magnusson K.P., Manolescu A., Karason A., Palsson A., Thorleifsson G.,
RA   Jakobsdottir M., Steinberg S., Palsson S., Jonasson F., Sigurgeirsson B.,
RA   Thorisdottir K., Ragnarsson R., Benediktsdottir K.R., Aben K.K.,
RA   Kiemeney L.A., Olafsson J.H., Gulcher J., Kong A., Thorsteinsdottir U.,
RA   Stefansson K.;
RT   "Genetic determinants of hair, eye and skin pigmentation in Europeans.";
RL   Nat. Genet. 39:1443-1452(2007).
RN   [25]
RP   VARIANTS OCA2 ILE-443; ASP-476; ARG-775 AND HIS-827.
RX   PubMed=17385796; DOI=10.1002/pd.1713;
RA   Hongyi L., Haiyun W., Hui Z., Qing W., Honglei D., Shu M., Weiying J.;
RT   "Prenatal diagnosis of oculocutaneous albinism type II and novel mutations
RT   in two Chinese families.";
RL   Prenat. Diagn. 27:502-506(2007).
RN   [26]
RP   INVOLVEMENT IN SHEP1, AND POLYMORPHISM.
RX   PubMed=18252221; DOI=10.1016/j.ajhg.2007.10.003;
RA   Kayser M., Liu F., Janssens A.C.J.W., Rivadeneira F., Lao O., van Duijn K.,
RA   Vermeulen M., Arp P., Jhamai M.M., van Ijcken W.F.J., den Dunnen J.T.,
RA   Heath S., Zelenika D., Despriet D.D.G., Klaver C.C.W., Vingerling J.R.,
RA   de Jong P.T.V.M., Hofman A., Aulchenko Y.S., Uitterlinden A.G.,
RA   Oostra B.A., van Duijn C.M.;
RT   "Three genome-wide association studies and a linkage analysis identify
RT   HERC2 as a human iris color gene.";
RL   Am. J. Hum. Genet. 82:411-423(2008).
RN   [27]
RP   VARIANT GLN-419, FUNCTION, INDUCTION, INVOLVEMENT IN SHEP1, INVOLVEMENT IN
RP   SUSCEPTIBILITY TO MELANOMA, AND POLYMORPHISM.
RX   PubMed=18252222; DOI=10.1016/j.ajhg.2007.11.005;
RA   Sturm R.A., Duffy D.L., Zhao Z.Z., Leite F.P.M., Stark M.S., Hayward N.K.,
RA   Martin N.G., Montgomery G.W.;
RT   "A single SNP in an evolutionary conserved region within intron 86 of the
RT   HERC2 gene determines human blue-brown eye color.";
RL   Am. J. Hum. Genet. 82:424-431(2008).
RN   [28]
RP   INVOLVEMENT IN SHEP1, POLYMORPHISM, AND INDUCTION.
RX   PubMed=18172690; DOI=10.1007/s00439-007-0460-x;
RA   Eiberg H., Troelsen J., Nielsen M., Mikkelsen A., Mengel-From J.,
RA   Kjaer K.W., Hansen L.;
RT   "Blue eye color in humans may be caused by a perfectly associated founder
RT   mutation in a regulatory element located within the HERC2 gene inhibiting
RT   OCA2 expression.";
RL   Hum. Genet. 123:177-187(2008).
RN   [29]
RP   VARIANTS OCA2 MET-404; TRP-419; ILE-633; CYS-679 AND CYS-684.
RX   PubMed=23504663; DOI=10.1002/humu.22315;
RA   Simeonov D.R., Wang X., Wang C., Sergeev Y., Dolinska M., Bower M.,
RA   Fischer R., Winer D., Dubrovsky G., Balog J.Z., Huizing M., Hart R.,
RA   Zein W.M., Gahl W.A., Brooks B.P., Adams D.R.;
RT   "DNA variations in oculocutaneous albinism: an updated mutation list and
RT   current outstanding issues in molecular diagnostics.";
RL   Hum. Mutat. 34:827-835(2013).
RN   [30]
RP   FUNCTION, CHANNEL ACTIVITY, CHARACTERIZATION OF VARIANTS OCA2 ILE-443 AND
RP   GLU-614, AND SUBCELLULAR LOCATION.
RX   PubMed=25513726; DOI=10.7554/elife.04543;
RA   Bellono N.W., Escobar I.E., Lefkovith A.J., Marks M.S., Oancea E.;
RT   "An intracellular anion channel critical for pigmentation.";
RL   Elife 3:e04543-e04543(2014).
CC   -!- FUNCTION: Contributes to a melanosome-specific anion (chloride) current
CC       that modulates melanosomal pH for optimal tyrosinase activity required
CC       for melanogenesis and the melanosome maturation (PubMed:25513726,
CC       PubMed:11310796, PubMed:15262401, PubMed:22234890). One of the
CC       components of the mammalian pigmentary system (PubMed:15262401,
CC       PubMed:18252222, PubMed:7601462). May serve as a key control point at
CC       which ethnic skin color variation is determined. Major determinant of
CC       brown and/or blue eye color (PubMed:15262401, PubMed:18252222,
CC       PubMed:7601462). Seems to regulate the post-translational processing of
CC       tyrosinase, which catalyzes the limiting reaction in melanin synthesis
CC       (By similarity). {ECO:0000250|UniProtKB:Q62052,
CC       ECO:0000269|PubMed:11310796, ECO:0000269|PubMed:15262401,
CC       ECO:0000269|PubMed:18252222, ECO:0000269|PubMed:22234890,
CC       ECO:0000269|PubMed:25513726, ECO:0000269|PubMed:7601462}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=chloride(in) = chloride(out); Xref=Rhea:RHEA:29823,
CC         ChEBI:CHEBI:17996; Evidence={ECO:0000305|PubMed:25513726};
CC   -!- SUBCELLULAR LOCATION: Melanosome membrane {ECO:0000269|PubMed:25513726,
CC       ECO:0000269|PubMed:7601462}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:7601462}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q04671-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q04671-2; Sequence=VSP_012284;
CC       Name=3;
CC         IsoId=Q04671-3; Sequence=VSP_012285, VSP_012286;
CC   -!- TISSUE SPECIFICITY: Expressed in melanocytes and retinal pigment
CC       epithelium. {ECO:0000269|PubMed:25513726, ECO:0000269|PubMed:32966160}.
CC   -!- DEVELOPMENTAL STAGE: Expressed at early stages of melanosome
CC       differentiation. {ECO:0000269|PubMed:32966160}.
CC   -!- INDUCTION: Expression is under the control of an enhancer element that
CC       is encoded in an intron of the close-by HERC2 gene. The enhancer
CC       element containing the T-allele of the polymorphism rs12913832 mediates
CC       binding of the transcription factors HLTF, LEF1 and MITF and increases
CC       OCA2 expression. In contrast, transcription factor binding and OCA2
CC       expression are reduced in carriers of the C-allele of polymorphism
CC       rs12913832. Thus, people homozygous for the C-allele have light-colored
CC       eyes, while people homozygous for the T-allele of polymorphism
CC       rs12913832 most often have brown eyes. {ECO:0000269|PubMed:18172690,
CC       ECO:0000269|PubMed:18252222, ECO:0000269|PubMed:22234890}.
CC   -!- POLYMORPHISM: Genetic variants in OCA2 define the skin/hair/eye
CC       pigmentation variation locus 1 (SHEP1) [MIM:227220]; also known as
CC       skin/hair/eye pigmentation type 1, blue/nonblue eyes or skin/hair/eye
CC       pigmentation type 1, blue/brown eyes or skin/hair/eye pigmentation type
CC       1, blond/brown hair or eye color, brown/blue or eye color, blue/nonblue
CC       or eye color type 3 (EYCL3) or brown eye color type 2 (BEY2) or hair
CC       color type 3 (HCL3). Hair, eye and skin pigmentation are among the most
CC       visible examples of human phenotypic variation, with a broad normal
CC       range that is subject to substantial geographic stratification. In the
CC       case of skin, individuals tend to have lighter pigmentation with
CC       increasing distance from the equator. By contrast, the majority of
CC       variation in human eye and hair color is found among individuals of
CC       European ancestry, with most other human populations fixed for brown
CC       eyes and black hair. OCA2 polymorphisms may act as a penetrance
CC       modifier of the risk of malignant melanoma.
CC       {ECO:0000269|PubMed:17236130, ECO:0000269|PubMed:17952075,
CC       ECO:0000269|PubMed:18172690, ECO:0000269|PubMed:18252221,
CC       ECO:0000269|PubMed:18252222}.
CC   -!- DISEASE: Albinism, oculocutaneous, 2 (OCA2) [MIM:203200]: An autosomal
CC       recessive disorder in which the biosynthesis of melanin pigment is
CC       reduced in skin, hair, and eyes. Although affected infants may appear
CC       at birth to have complete absence of melanin pigment, most patients
CC       acquire small amounts of pigment with age. Visual anomalies include
CC       decreased acuity and nystagmus. The phenotype is highly variable. The
CC       hair of affected individuals may turn darker with age, and pigmented
CC       nevi or freckles may be seen. African and African American individuals
CC       may have yellow hair and blue-gray or hazel irides. One phenotypic
CC       variant, 'brown OCA,' has been described in African and African
CC       American populations and is characterized by light brown hair and skin
CC       color and gray to tan irides. {ECO:0000269|PubMed:10649493,
CC       ECO:0000269|PubMed:10671067, ECO:0000269|PubMed:10987646,
CC       ECO:0000269|PubMed:12713581, ECO:0000269|PubMed:12727022,
CC       ECO:0000269|PubMed:12876664, ECO:0000269|PubMed:17385796,
CC       ECO:0000269|PubMed:23504663, ECO:0000269|PubMed:25513726,
CC       ECO:0000269|PubMed:7762554, ECO:0000269|PubMed:7874125,
CC       ECO:0000269|PubMed:9259203}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the CitM (TC 2.A.11) transporter family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Mutations of the P gene; Note=Retina International's
CC       Scientific Newsletter;
CC       URL="https://www.retina-international.org/files/sci-news/pgenemut.htm";
CC   -!- WEB RESOURCE: Name=Albinism database (ADB); Note=P mutations;
CC       URL="http://www.ifpcs.org/albinism/oca2mut.html";
CC   -!- WEB RESOURCE: Name=Protein Spotlight; Note=Questioning colour - Issue
CC       54 of January 2005;
CC       URL="https://web.expasy.org/spotlight/back_issues/054";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M99564; AAA36477.1; -; mRNA.
DR   EMBL; U19170; AAC13783.1; -; Genomic_DNA.
DR   EMBL; U19153; AAC13783.1; JOINED; Genomic_DNA.
DR   EMBL; U19154; AAC13783.1; JOINED; Genomic_DNA.
DR   EMBL; U19156; AAC13783.1; JOINED; Genomic_DNA.
DR   EMBL; U19158; AAC13783.1; JOINED; Genomic_DNA.
DR   EMBL; U19160; AAC13783.1; JOINED; Genomic_DNA.
DR   EMBL; U19162; AAC13783.1; JOINED; Genomic_DNA.
DR   EMBL; U19164; AAC13783.1; JOINED; Genomic_DNA.
DR   EMBL; U19166; AAC13783.1; JOINED; Genomic_DNA.
DR   EMBL; U19169; AAC13783.1; JOINED; Genomic_DNA.
DR   EMBL; U19168; AAC13783.1; JOINED; Genomic_DNA.
DR   EMBL; U19167; AAC13783.1; JOINED; Genomic_DNA.
DR   EMBL; U19165; AAC13783.1; JOINED; Genomic_DNA.
DR   EMBL; U19163; AAC13783.1; JOINED; Genomic_DNA.
DR   EMBL; U19161; AAC13783.1; JOINED; Genomic_DNA.
DR   EMBL; U19159; AAC13783.1; JOINED; Genomic_DNA.
DR   EMBL; U19157; AAC13783.1; JOINED; Genomic_DNA.
DR   EMBL; U19155; AAC13783.1; JOINED; Genomic_DNA.
DR   EMBL; U19176; AAC13784.1; -; Genomic_DNA.
DR   EMBL; U19153; AAC13784.1; JOINED; Genomic_DNA.
DR   EMBL; U19154; AAC13784.1; JOINED; Genomic_DNA.
DR   EMBL; U19155; AAC13784.1; JOINED; Genomic_DNA.
DR   EMBL; U19157; AAC13784.1; JOINED; Genomic_DNA.
DR   EMBL; U19158; AAC13784.1; JOINED; Genomic_DNA.
DR   EMBL; U19159; AAC13784.1; JOINED; Genomic_DNA.
DR   EMBL; U19160; AAC13784.1; JOINED; Genomic_DNA.
DR   EMBL; U19161; AAC13784.1; JOINED; Genomic_DNA.
DR   EMBL; U19162; AAC13784.1; JOINED; Genomic_DNA.
DR   EMBL; U19163; AAC13784.1; JOINED; Genomic_DNA.
DR   EMBL; U19164; AAC13784.1; JOINED; Genomic_DNA.
DR   EMBL; U19165; AAC13784.1; JOINED; Genomic_DNA.
DR   EMBL; U19166; AAC13784.1; JOINED; Genomic_DNA.
DR   EMBL; U19167; AAC13784.1; JOINED; Genomic_DNA.
DR   EMBL; U19168; AAC13784.1; JOINED; Genomic_DNA.
DR   EMBL; U19169; AAC13784.1; JOINED; Genomic_DNA.
DR   EMBL; U19171; AAC13784.1; JOINED; Genomic_DNA.
DR   EMBL; U19172; AAC13784.1; JOINED; Genomic_DNA.
DR   EMBL; U19173; AAC13784.1; JOINED; Genomic_DNA.
DR   EMBL; U19174; AAC13784.1; JOINED; Genomic_DNA.
DR   EMBL; U19175; AAC13784.1; JOINED; Genomic_DNA.
DR   EMBL; BC012097; AAH12097.1; -; mRNA.
DR   EMBL; M97901; AAA36430.1; -; mRNA.
DR   CCDS; CCDS10020.1; -. [Q04671-1]
DR   CCDS; CCDS73701.1; -. [Q04671-2]
DR   PIR; A57173; A57173.
DR   PIR; S28911; S28911.
DR   RefSeq; NP_000266.2; NM_000275.2. [Q04671-1]
DR   RefSeq; NP_001287913.1; NM_001300984.1. [Q04671-2]
DR   AlphaFoldDB; Q04671; -.
DR   BioGRID; 111002; 5.
DR   IntAct; Q04671; 3.
DR   STRING; 9606.ENSP00000346659; -.
DR   TCDB; 2.A.45.2.1; the arsenite-antimonite (arsb) efflux family.
DR   GlyCosmos; Q04671; 5 sites, No reported glycans.
DR   GlyGen; Q04671; 6 sites, 1 O-linked glycan (1 site).
DR   iPTMnet; Q04671; -.
DR   PhosphoSitePlus; Q04671; -.
DR   BioMuta; OCA2; -.
DR   DMDM; 90110050; -.
DR   MassIVE; Q04671; -.
DR   PaxDb; Q04671; -.
DR   PeptideAtlas; Q04671; -.
DR   Antibodypedia; 22329; 204 antibodies from 25 providers.
DR   DNASU; 4948; -.
DR   Ensembl; ENST00000353809.9; ENSP00000261276.8; ENSG00000104044.16. [Q04671-2]
DR   Ensembl; ENST00000354638.8; ENSP00000346659.3; ENSG00000104044.16. [Q04671-1]
DR   GeneID; 4948; -.
DR   KEGG; hsa:4948; -.
DR   MANE-Select; ENST00000354638.8; ENSP00000346659.3; NM_000275.3; NP_000266.2.
DR   UCSC; uc001zbh.6; human. [Q04671-1]
DR   AGR; HGNC:8101; -.
DR   CTD; 4948; -.
DR   DisGeNET; 4948; -.
DR   GeneCards; OCA2; -.
DR   GeneReviews; OCA2; -.
DR   HGNC; HGNC:8101; OCA2.
DR   HPA; ENSG00000104044; Tissue enriched (choroid).
DR   MalaCards; OCA2; -.
DR   MIM; 203200; phenotype.
DR   MIM; 227220; phenotype.
DR   MIM; 611409; gene.
DR   neXtProt; NX_Q04671; -.
DR   OpenTargets; ENSG00000104044; -.
DR   Orphanet; 98794; Angelman syndrome due to maternal 15q11q13 deletion.
DR   Orphanet; 79432; Oculocutaneous albinism type 2.
DR   Orphanet; 98754; Prader-Willi syndrome due to maternal uniparental disomy of chromosome 15.
DR   Orphanet; 177901; Prader-Willi syndrome due to paternal deletion of 15q11q13 type 1.
DR   Orphanet; 177904; Prader-Willi syndrome due to paternal deletion of 15q11q13 type 2.
DR   PharmGKB; PA31890; -.
DR   VEuPathDB; HostDB:ENSG00000104044; -.
DR   eggNOG; KOG2639; Eukaryota.
DR   GeneTree; ENSGT01030000234550; -.
DR   HOGENOM; CLU_011920_2_1_1; -.
DR   InParanoid; Q04671; -.
DR   OMA; HHRIRDK; -.
DR   OrthoDB; 5481761at2759; -.
DR   PhylomeDB; Q04671; -.
DR   TreeFam; TF323556; -.
DR   PathwayCommons; Q04671; -.
DR   Reactome; R-HSA-5662702; Melanin biosynthesis.
DR   SignaLink; Q04671; -.
DR   SIGNOR; Q04671; -.
DR   BioGRID-ORCS; 4948; 8 hits in 1142 CRISPR screens.
DR   ChiTaRS; OCA2; human.
DR   GeneWiki; OCA2; -.
DR   GenomeRNAi; 4948; -.
DR   Pharos; Q04671; Tbio.
DR   PRO; PR:Q04671; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   RNAct; Q04671; protein.
DR   Bgee; ENSG00000104044; Expressed in pigmented layer of retina and 146 other tissues.
DR   ExpressionAtlas; Q04671; baseline and differential.
DR   Genevisible; Q04671; HS.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IDA:UniProtKB.
DR   GO; GO:0010008; C:endosome membrane; IDA:UniProtKB.
DR   GO; GO:0005765; C:lysosomal membrane; IDA:UniProtKB.
DR   GO; GO:0033162; C:melanosome membrane; IDA:UniProtKB.
DR   GO; GO:0061778; F:intracellular chloride channel activity; IDA:UniProtKB.
DR   GO; GO:0008283; P:cell population proliferation; IEA:Ensembl.
DR   GO; GO:0035752; P:lysosomal lumen pH elevation; IDA:UniProtKB.
DR   GO; GO:0042438; P:melanin biosynthetic process; IBA:GO_Central.
DR   GO; GO:0006583; P:melanin biosynthetic process from tyrosine; IDA:UniProtKB.
DR   GO; GO:0030318; P:melanocyte differentiation; IBA:GO_Central.
DR   GO; GO:0007286; P:spermatid development; IEA:Ensembl.
DR   CDD; cd01116; P_permease; 1.
DR   InterPro; IPR004680; Cit_transptr-like_dom.
DR   PANTHER; PTHR43568; P PROTEIN; 1.
DR   PANTHER; PTHR43568:SF1; P PROTEIN; 1.
DR   Pfam; PF03600; CitMHS; 1.
PE   1: Evidence at protein level;
KW   Albinism; Alternative splicing; Disease variant; Glycoprotein; Membrane;
KW   Reference proteome; Transmembrane; Transmembrane helix; Transport.
FT   CHAIN           1..838
FT                   /note="P protein"
FT                   /id="PRO_0000172509"
FT   TOPO_DOM        1..179
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        180..197
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        198..330
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        331..347
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        348..353
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        354..370
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        371..384
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        385..401
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        402..423
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        424..440
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        441..513
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        514..530
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        531..620
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        621..637
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        638..647
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        648..664
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        665..679
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        680..696
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        697..720
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        721..737
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        738..760
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        761..777
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        778..817
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        818..834
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        835..838
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   REGION          38..60
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          74..94
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   CARBOHYD        214
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        218
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        273
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        442
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        781
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   VAR_SEQ         349..372
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_012284"
FT   VAR_SEQ         652..668
FT                   /note="WIAILGAIWLLILADIH -> GLGLVQAGRYYLSTPES (in isoform
FT                   3)"
FT                   /evidence="ECO:0000303|PubMed:8421497"
FT                   /id="VSP_012285"
FT   VAR_SEQ         669..838
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:8421497"
FT                   /id="VSP_012286"
FT   VARIANT         10
FT                   /note="R -> W (in OCA2; dbSNP:rs554862186)"
FT                   /evidence="ECO:0000269|PubMed:12713581"
FT                   /id="VAR_020622"
FT   VARIANT         27
FT                   /note="G -> R (in OCA2; dbSNP:rs61738394)"
FT                   /id="VAR_006117"
FT   VARIANT         86
FT                   /note="S -> R (in OCA2; dbSNP:rs772243109)"
FT                   /evidence="ECO:0000269|PubMed:10671067"
FT                   /id="VAR_006118"
FT   VARIANT         112
FT                   /note="C -> F (in OCA2; dbSNP:rs562649990)"
FT                   /evidence="ECO:0000269|PubMed:10671067"
FT                   /id="VAR_006119"
FT   VARIANT         198
FT                   /note="P -> L (in OCA2; dbSNP:rs183487020)"
FT                   /evidence="ECO:0000269|PubMed:12713581"
FT                   /id="VAR_020623"
FT   VARIANT         206..211
FT                   /note="Missing (in OCA2; severe)"
FT                   /id="VAR_006120"
FT   VARIANT         211
FT                   /note="P -> L (in OCA2; dbSNP:rs190612616)"
FT                   /evidence="ECO:0000269|PubMed:12713581"
FT                   /id="VAR_020624"
FT   VARIANT         241
FT                   /note="P -> R (in dbSNP:rs2305253)"
FT                   /id="VAR_022019"
FT   VARIANT         257
FT                   /note="A -> D (in dbSNP:rs1050968)"
FT                   /evidence="ECO:0000269|PubMed:10671067,
FT                   ECO:0000269|PubMed:8421497"
FT                   /id="VAR_006121"
FT   VARIANT         266
FT                   /note="R -> W (in dbSNP:rs33929465)"
FT                   /id="VAR_032094"
FT   VARIANT         273..274
FT                   /note="NW -> KV (in OCA2; dbSNP:rs797044784)"
FT                   /id="VAR_006122"
FT   VARIANT         290
FT                   /note="R -> G (in OCA2; dbSNP:rs769408559)"
FT                   /evidence="ECO:0000269|PubMed:10987646,
FT                   ECO:0000269|PubMed:12876664"
FT                   /id="VAR_020625"
FT   VARIANT         305
FT                   /note="R -> W (associated with nonblue eye color; could be
FT                   a biomarker of cutaneous cancer risk; dbSNP:rs1800401)"
FT                   /evidence="ECO:0000269|PubMed:10987646,
FT                   ECO:0000269|PubMed:12163334, ECO:0000269|PubMed:15889046,
FT                   ECO:0000269|PubMed:7601462"
FT                   /id="VAR_006123"
FT   VARIANT         334
FT                   /note="A -> V (in OCA2; dbSNP:rs121918168)"
FT                   /evidence="ECO:0000269|PubMed:10649493"
FT                   /id="VAR_020626"
FT   VARIANT         336
FT                   /note="A -> V (in dbSNP:rs34010619)"
FT                   /id="VAR_032095"
FT   VARIANT         350
FT                   /note="V -> M (in unclassified OCA; dbSNP:rs533478642)"
FT                   /evidence="ECO:0000269|PubMed:10649493"
FT                   /id="VAR_020627"
FT   VARIANT         368
FT                   /note="A -> V (in OCA2; dbSNP:rs61745150)"
FT                   /evidence="ECO:0000269|PubMed:10671067"
FT                   /id="VAR_006124"
FT   VARIANT         370
FT                   /note="I -> T (in unclassified OCA; dbSNP:rs34731820)"
FT                   /evidence="ECO:0000269|PubMed:10649493"
FT                   /id="VAR_020628"
FT   VARIANT         385
FT                   /note="F -> I (in OCA2; severe; dbSNP:rs137956605)"
FT                   /id="VAR_006125"
FT   VARIANT         387
FT                   /note="T -> M (in dbSNP:rs150335311)"
FT                   /evidence="ECO:0000269|PubMed:12713581"
FT                   /id="VAR_020629"
FT   VARIANT         394
FT                   /note="M -> I (in OCA2; dbSNP:rs121918171)"
FT                   /evidence="ECO:0000269|PubMed:12713581"
FT                   /id="VAR_020630"
FT   VARIANT         395
FT                   /note="M -> L (in OCA2; severe; dbSNP:rs757286784)"
FT                   /id="VAR_006126"
FT   VARIANT         404
FT                   /note="T -> M (in OCA2; dbSNP:rs144812594)"
FT                   /evidence="ECO:0000269|PubMed:23504663"
FT                   /id="VAR_006127"
FT   VARIANT         419
FT                   /note="R -> Q (associated with green/hazel eye color;
FT                   dbSNP:rs1800407)"
FT                   /evidence="ECO:0000269|PubMed:10987646,
FT                   ECO:0000269|PubMed:12163334, ECO:0000269|PubMed:15889046,
FT                   ECO:0000269|PubMed:18252222, ECO:0000269|PubMed:7601462"
FT                   /id="VAR_006128"
FT   VARIANT         419
FT                   /note="R -> W (in OCA2; dbSNP:rs143218168)"
FT                   /evidence="ECO:0000269|PubMed:23504663"
FT                   /id="VAR_006129"
FT   VARIANT         425
FT                   /note="Missing (in OCA2; mild; dbSNP:rs752510351)"
FT                   /id="VAR_006130"
FT   VARIANT         440
FT                   /note="L -> F (in dbSNP:rs1800408)"
FT                   /evidence="ECO:0000269|PubMed:7601462"
FT                   /id="VAR_007939"
FT   VARIANT         440
FT                   /note="L -> H"
FT                   /id="VAR_006131"
FT   VARIANT         443
FT                   /note="V -> I (in OCA2; reduced flow of chloride ions; no
FT                   effect on subcellular location; slightly increased luminal
FT                   pH; dbSNP:rs121918166)"
FT                   /evidence="ECO:0000269|PubMed:10987646,
FT                   ECO:0000269|PubMed:12876664, ECO:0000269|PubMed:17385796,
FT                   ECO:0000269|PubMed:25513726"
FT                   /id="VAR_006132"
FT   VARIANT         446
FT                   /note="M -> V (in OCA2; mild; AROA form;
FT                   dbSNP:rs140566426)"
FT                   /id="VAR_006133"
FT   VARIANT         473
FT                   /note="I -> S (in OCA2)"
FT                   /id="VAR_006134"
FT   VARIANT         476
FT                   /note="N -> D (in OCA2)"
FT                   /evidence="ECO:0000269|PubMed:17385796"
FT                   /id="VAR_043700"
FT   VARIANT         481
FT                   /note="A -> T (in OCA2; dbSNP:rs74653330)"
FT                   /evidence="ECO:0000269|PubMed:12713581,
FT                   ECO:0000269|PubMed:12727022"
FT                   /id="VAR_007940"
FT   VARIANT         489
FT                   /note="N -> D (in OCA2; mild/severe; dbSNP:rs121918170)"
FT                   /evidence="ECO:0000269|PubMed:12876664"
FT                   /id="VAR_006135"
FT   VARIANT         519
FT                   /note="V -> A (in dbSNP:rs41446944)"
FT                   /id="VAR_032096"
FT   VARIANT         549
FT                   /note="H -> Q (in OCA2)"
FT                   /id="VAR_006136"
FT   VARIANT         560
FT                   /note="R -> H (in dbSNP:rs35110389)"
FT                   /id="VAR_032097"
FT   VARIANT         592
FT                   /note="T -> I (in OCA2; dbSNP:rs1800413)"
FT                   /evidence="ECO:0000269|PubMed:10671067"
FT                   /id="VAR_006137"
FT   VARIANT         614
FT                   /note="K -> E (in OCA2; no effect on flow of chloride ions;
FT                   no effect on subcellular location; no effect on luminal
FT                   pH)"
FT                   /evidence="ECO:0000269|PubMed:10987646,
FT                   ECO:0000269|PubMed:25513726"
FT                   /id="VAR_020631"
FT   VARIANT         614
FT                   /note="K -> N (in OCA2)"
FT                   /id="VAR_006138"
FT   VARIANT         615
FT                   /note="H -> R (in dbSNP:rs1800414)"
FT                   /evidence="ECO:0000269|PubMed:12713581,
FT                   ECO:0000269|PubMed:7601462"
FT                   /id="VAR_006139"
FT   VARIANT         617
FT                   /note="I -> L (in OCA2; dbSNP:rs763016773)"
FT                   /evidence="ECO:0000269|PubMed:10987646"
FT                   /id="VAR_020632"
FT   VARIANT         633
FT                   /note="V -> I (in OCA2; dbSNP:rs1372200062)"
FT                   /evidence="ECO:0000269|PubMed:23504663"
FT                   /id="VAR_072600"
FT   VARIANT         652
FT                   /note="W -> R (in OCA2; dbSNP:rs886043514)"
FT                   /id="VAR_006140"
FT   VARIANT         678
FT                   /note="E -> K (in unclassified OCA)"
FT                   /evidence="ECO:0000269|PubMed:10649493"
FT                   /id="VAR_020633"
FT   VARIANT         679
FT                   /note="W -> C (in OCA2; dbSNP:rs121918169)"
FT                   /evidence="ECO:0000269|PubMed:10987646,
FT                   ECO:0000269|PubMed:12876664, ECO:0000269|PubMed:23504663"
FT                   /id="VAR_020634"
FT   VARIANT         679
FT                   /note="W -> R (in OCA2; severe; dbSNP:rs751822606)"
FT                   /id="VAR_006141"
FT   VARIANT         684
FT                   /note="F -> C (in OCA2; dbSNP:rs772754008)"
FT                   /evidence="ECO:0000269|PubMed:23504663"
FT                   /id="VAR_072601"
FT   VARIANT         688
FT                   /note="L -> F (in unclassified OCA)"
FT                   /evidence="ECO:0000269|PubMed:10649493"
FT                   /id="VAR_020635"
FT   VARIANT         720
FT                   /note="R -> C (in OCA2; dbSNP:rs141545475)"
FT                   /evidence="ECO:0000269|PubMed:10987646"
FT                   /id="VAR_020636"
FT   VARIANT         722
FT                   /note="I -> T (in dbSNP:rs1800417)"
FT                   /evidence="ECO:0000269|PubMed:7601462"
FT                   /id="VAR_006142"
FT   VARIANT         724
FT                   /note="A -> P (in OCA2)"
FT                   /evidence="ECO:0000269|PubMed:10671067"
FT                   /id="VAR_006143"
FT   VARIANT         736
FT                   /note="S -> L (in OCA2; dbSNP:rs780296175)"
FT                   /id="VAR_006144"
FT   VARIANT         743
FT                   /note="P -> L (in OCA2 and unclassified OCA;
FT                   dbSNP:rs121918167)"
FT                   /evidence="ECO:0000269|PubMed:10649493,
FT                   ECO:0000269|PubMed:12876664"
FT                   /id="VAR_006145"
FT   VARIANT         773
FT                   /note="A -> T (in a breast cancer sample; somatic mutation;
FT                   dbSNP:rs1184589806)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036468"
FT   VARIANT         775
FT                   /note="G -> R (in OCA2)"
FT                   /evidence="ECO:0000269|PubMed:17385796"
FT                   /id="VAR_043701"
FT   VARIANT         787
FT                   /note="A -> V (in OCA2; dbSNP:rs200457227)"
FT                   /evidence="ECO:0000269|PubMed:10671067"
FT                   /id="VAR_006146"
FT   VARIANT         795
FT                   /note="G -> R (in OCA2)"
FT                   /evidence="ECO:0000269|PubMed:10987646"
FT                   /id="VAR_020637"
FT   VARIANT         799
FT                   /note="Q -> H (in OCA2)"
FT                   /evidence="ECO:0000269|PubMed:12727022"
FT                   /id="VAR_020638"
FT   VARIANT         827
FT                   /note="Y -> H (in OCA2; dbSNP:rs1255943449)"
FT                   /evidence="ECO:0000269|PubMed:17385796"
FT                   /id="VAR_043702"
FT   VARIANT         833
FT                   /note="Missing (in OCA2; dbSNP:rs751440917)"
FT                   /evidence="ECO:0000269|PubMed:10987646"
FT                   /id="VAR_021682"
SQ   SEQUENCE   838 AA;  92850 MW;  A6158B9E55BD7199 CRC64;
     MHLEGRDGRR YPGAPAVELL QTSVPSGLAE LVAGKRRLPR GAGGADPSHS CPRGAAGQSS
     WAPAGQEFAS FLTKGRSHSS LPQMSSSRSK DSCFTENTPL LRNSLQEKGS RCIPVYHPEF
     ITAEESWEDS SADWERRYLL SREVSGLSAS ASSEKGDLLD SPHIRLRLSK LRRCVQWLKV
     MGLFAFVVLC SILFSLYPDQ GKLWQLLALS PLENYSVNLS SHVDSTLLQV DLAGALVASG
     PSRPGREEHI VVELTQADAL GSRWRRPQQV THNWTVYLNP RRSEHSVMSR TFEVLTRETV
     SISIRASLQQ TQAVPLLMAH QYLRGSVETQ VTIATAILAG VYALIIFEIV HRTLAAMLGS
     LAALAALAVI GDRPSLTHVV EWIDFETLAL LFGMMILVAI FSETGFFDYC AVKAYRLSRG
     RVWAMIIMLC LIAAVLSAFL DNVTTMLLFT PVTIRLCEVL NLDPRQVLIA EVIFTNIGGA
     ATAIGDPPNV IIVSNQELRK MGLDFAGFTA HMFIGICLVL LVCFPLLRLL YWNRKLYNKE
     PSEIVELKHE IHVWRLTAQR ISPASREETA VRRLLLGKVL ALEHLLARRL HTFHRQISQE
     DKNWETNIQE LQKKHRISDG ILLAKCLTVL GFVIFMFFLN SFVPGIHLDL GWIAILGAIW
     LLILADIHDF EIILHRVEWA TLLFFAALFV LMEALAHLHL IEYVGEQTAL LIKMVPEEQR
     LIAAIVLVVW VSALASSLID NIPFTATMIP VLLNLSHDPE VGLPAPPLMY ALAFGACLGG
     NGTLIGASAN VVCAGIAEQH GYGFSFMEFF RLGFPMMVVS CTVGMCYLLV AHVVVGWN
//
